Last 397.50 GBp
Change Today 0.00 / 0.00%
Volume 481.0
DDDD On Other Exchanges
Symbol
Exchange
London
As of 7:35 AM 12/24/14 All times are local (Market data is delayed by at least 15 minutes).

4d pharma plc (DDDD) Snapshot

Open
397.50 GBp
Previous Close
397.50 GBp
Day High
397.50 GBp
Day Low
397.50 GBp
52 Week High
09/9/14 - 412.50 GBp
52 Week Low
02/17/14 - 100.00 GBp
Market Cap
207.1M
Average Volume 10 Days
11.4K
EPS TTM
--
Shares Outstanding
52.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for 4D PHARMA PLC (DDDD)

Related News

No related news articles were found.

4d pharma plc (DDDD) Related Businessweek News

No Related Businessweek News Found

4d pharma plc (DDDD) Details

4D pharma plc, a pharmaceutical company, focuses on developing projects for new therapeutic areas in the United Kingdom. The company’s proprietary platform includes MicroRx, which discovers bacteria with therapeutic effects in target disease areas. It offers Blautix for the treatment of irritable bowel syndrome; Thetanix, a live biotherapeutic for the treatment of paediatric crohns; and Rosburix for the treatment of paediatric colitis. The company was formerly known as Schosween 18 Limited. 4D pharma plc was incorporated in 2014 and is headquartered in Manchester, the United Kingdom.

Founded in 2014

4d pharma plc (DDDD) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

4d pharma plc (DDDD) Key Developments

4D Pharma plc Reports Unaudited Consolidated Earnings Results for the Period from 10 January 2014 to 30 June 2014

4D pharma plc reported unaudited consolidated earnings results for the period from 10 January 2014 to 30 June 2014. For the period, the company reported revenue of £116,000, operating loss of £521,000, loss on ordinary activities before taxation and minority interest of £501,000, loss for the period and total comprehensive loss for the period of £464,000 or 1.43 pence per basic and diluted share. Net cash outflow from operating activities was £164,000 and purchases of tangible fixed assets of £219,000.

4D Pharma Receives Orphan Drug Designation from FDA for Rosburix

4D pharma plc announced that the U.S. Food and Drug Administration has granted orphan drug designation for Rosburix™, for the treatment of ulcerative colitis in paediatric patients. Rosburix™ is 4D's second live biotherapeutic to receive orphan designation, having received orphan designation from the FDA for the treatment of paediatric Crohns with Thetanix™ in September 2013. PUC is an inflammation, or painful swelling of the lining of the large intestine or colon. The inflammation can lead to sores and ulcers which can bleed, produce pus and cause pain. Although some patients with PUC do show periods of remission, PUC is a long term condition, requiring management throughout their life. Despite a number of approved therapeutic options for treatment, surgical removal of the colon is still required in many cases and in the US it is estimated that 8% of paediatric patients undergo colectomy at 1 year, 15% at 3 years, and 20% at 5 years following diagnosis.

4D pharma Mulls IPO

4D pharma plc is looking to list on London's junior market in late February 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DDDD:LN 397.50 GBp 0.00

DDDD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for DDDD.
View Industry Companies
 

Industry Analysis

DDDD

Industry Average

Valuation DDDD Industry Range
No financial data is available for DDDD.
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact 4D PHARMA PLC, please visit www.4dpharmaplc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.